Literature DB >> 14962762

Animal models of type I allergy using recombinant allergens.

Udo Herz1, Harald Renz, Ursula Wiedermann.   

Abstract

Various animal models including guinea pigs, monkeys, dogs, rats, and mice have been established in an attempt to provide insights into the complex immunological and pathophysiological mechanisms of human type I allergic diseases. The detailed knowledge of the murine genome, the various components of the murine immune system, and the generation of engineered mice has made the murine system the most attractive among all animal models. The availability of multitude technologies and reagents to characterize and manipulate immunological pathways and mediators adds to the outstanding opportunities to assess the pathology of allergic diseases and to develop novel therapeutic strategies in mice. Numerous sensitization protocols with food and aero-allergens are used to establish an allergic/asthma-like phenotype in mice. Requirements for an appropriate murine model include a close resemblance to the pathology of the disease in humans, the objective measurement of the physiologic parameters, as well as reliability and reproducibility of the experimental data. With respect to reproducible experimental conditions, it has been recognized that extract preparations from natural allergen sources can vary in their allergen-content and -composition. This might influence the degree of sensitization or the outcome of treatment strategies in dependence of the applied extract preparation. The use of recombinant allergens in experimental in vivo and in vitro systems can overcome these problems. Another aspect, that has become obvious from the experimental studies, is that allergens can differ in their immunogenicity as well as in their capacity to act as tolerogens. Therefore, it seems important that the efficacy of the different allergen-molecules to act as therapeutic agents is individually examined. In this review, examples of animal models are described, in which recombinant allergens have been used for sensitization and/or treatment of allergic responses and how they have been used to enhance our understanding of the pathology of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962762     DOI: 10.1016/j.ymeth.2003.08.013

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  14 in total

1.  Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Authors:  Ulrike Baranyi; Birgit Linhart; Nina Pilat; Martina Gattringer; Jessamyn Bagley; Ferdinand Muehlbacher; John Iacomini; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 2.  Murine models for mucosal tolerance in allergy.

Authors:  Ursula Smole; Irma Schabussova; Winfried F Pickl; Ursula Wiedermann
Journal:  Semin Immunol       Date:  2017-08-12       Impact factor: 11.130

3.  Loss of GTPase of immunity-associated protein 5 (Gimap5) promotes pathogenic CD4+ T-cell development and allergic airway disease.

Authors:  Andrew R Patterson; Paige Bolcas; Kristin Lampe; Rachel Cantrell; Brandy Ruff; Ian Lewkowich; Simon P Hogan; Edith M Janssen; Jack Bleesing; Gurjit K Khurana Hershey; Kasper Hoebe
Journal:  J Allergy Clin Immunol       Date:  2018-10-25       Impact factor: 10.793

4.  A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells.

Authors:  Peta J O'Connell; Xiangbin Wang; Matilde Leon-Ponte; Corrie Griffiths; Sandeep C Pingle; Gerard P Ahern
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

5.  Induction of a Th1 immune response and suppression of IgE via immunotherapy with a recombinant hybrid molecule encapsulated in liposome-protamine-DNA nanoparticles in a model of experimental allergy.

Authors:  Hamid Reza Nouri; Abdolreza Varasteh; Mahmoud Reza Jaafari; Janet M Davies; Mojtaba Sankian
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

6.  Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation.

Authors:  Tolga Akkoc; Liam O'Mahony; Ruth Ferstl; Cezmi Akdis; Tunc Akkoc
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

7.  T-bet expression by dendritic cells is required for the repolarization of allergic airway inflammation.

Authors:  Karin L Heckman; Suresh Radhakrishnan; Tobias Peikert; Koji Iijima; Hugh C McGregor; Michael P Bell; Hirohito Kita; Larry R Pease
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

Review 8.  New insights on mast cell activation via the high affinity receptor for IgE.

Authors:  Juan Rivera; Nora A Fierro; Ana Olivera; Ryo Suzuki
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

9.  Th1 and Th2 cells are required for both eosinophil- and neutrophil-associated airway inflammatory responses in mice.

Authors:  Romy Fischer; Daniel Tomé; Jerry R McGhee; Prosper N Boyaka
Journal:  Biochem Biophys Res Commun       Date:  2007-03-19       Impact factor: 3.575

10.  Adverse effect of nano-silicon dioxide on lung function of rats with or without ovalbumin immunization.

Authors:  Bing Han; Jing Guo; Tesfamariam Abrahaley; Longjuan Qin; Li Wang; Yuduo Zheng; Bing Li; Dandan Liu; Hanchao Yao; Jiwen Yang; Changming Li; Zhuge Xi; Xu Yang
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.